ClinicalTrials.gg
CompletedNCT00429936Updated Jun 22, 2010

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

A Phase 2 interventional study of Fenretinide in Geographic Atrophy and Dry Age Related Macular Degeneration, sponsored by Sirion Therapeutics, Inc.. Completed. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2010-06-22.

Sponsored by Sirion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
50 Years to 89 Years
Sex
All
01

Study summary

The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).

02

Conditions studied

  • Geographic Atrophy
  • Dry Age Related Macular Degeneration

Browse trials for

Keywords

  • Dry Age Related Macular Degeneration
  • Geographic Atrophy
03

In context

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's enrollment of 245 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Sirion Therapeutics, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • males or females, 50 to 89 years of age
  • must have GA from AMD in one or both eyes

Exclusion criteria

Exclusion Criteria:

  • GA due to any disease other than AMD (eg, drug-induced)
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
245 participants (actual)

Study arms

  • Active comparator
    100 mg fenretinide softgel capsules

    Three (3) 100-mg fenretinide softgel capsules

    Drug: Fenretinide

  • Active comparator
    Fenretinide and placebo softgel capsules

    One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules

    Drug: Fenretinide

  • Placebo comparator
    Placebo softgel capsules

    Three (3) placebo softgel capsules

    Drug: Fenretinide

Interventions

  • Once daily 30 minutes after the evening meal for 24 months

06

What researchers measure

Primary outcomes

  1. GA lesion progression

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Yeong JL, Loveman E, Colquitt JL, Royle P, Waugh N, Lois N. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD013154. doi: 10.1002/14651858.CD013154.pub2. PubMed 33331670 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2007
First posted
Feb 1, 2007
Start
Dec 2006
Primary completionActual
May 2010
CompletionActual
May 2010
Last update
Jun 22, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00429936
Lead sponsor
Sirion Therapeutics, Inc.
Collaborators
ReVision Therapeutics, Inc.
First posted
Feb 1, 2007
Start date
Dec 2006
Primary completion
May 2010
Completion
May 2010
Last update
Jun 22, 2010

Study contacts

Roger Vogel, MD
study director · ReVision Therapeutics Advisor

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenretinide

Start the discussion